The company maintains offices and laboratories in its South Florida Headquarters. The company holds all IP for the delivery of pharmaceutical, nutritional and cosmetic active ingredients utilizing its patented technology.
The TDS Technology developed by TransDermal Technologies and the Langford Institute now transferred to TDSC stands alone as a unique platform for rapid delivery of most drugs, nutritional or cosmetic actives across intact skin. The system is capable of delivering bolus doses of up to 500 milligrams within seconds to minutes with 95+% efficiency and has delivered up to small peptides in molecular weight. The TDS Technology mimics the physical chemistry of compounds which readily transmigrate the skin. The Company, through its subsidiary Hormone Replacement Technologies, Inc. (www.hrtinc.us) is funded to complete registration of TDS Testosterone 50mg/mL and one other hormone. TDSC will also develop applications of Non-Steroidal Anti-inflammatory Drugs, Anti-infectives and other acute pain remedies in the near future.
TDS applications are dosed via means of a metered pump sprayer, rubbed into the skin and rapidly absorbed. The system has been successfully tested in 18 applications including in 4 human studies and including several compounds that have not before been successfully delivered transdermally including Morphine Sulphate and Diazepam.
TDSC is developing the TDS Technology across multiple therapeutic categories. The company is currently preparing to initiate phase 3 trials for a 505(b)2 approval of a significant product in the Hormone Replacement space. The company has placed the license for this product into a company structure along with two products in the women's HRT space and a 4th product which will have broad appeal. The company plans to develop on product to registration and a second to at least phase 2 and then vend the company to a well-positioned partner with strengths in both men's and women's health, particularly hormone replacement. The company may consider a license for one of the products to particularly well-positioned partner.
The plan forward will be to follow a similar model of grouping related licenses in subsidiary companies, capitalizing them to develop the applications and then selling the company pre-sales. The company has the capability to formulate, test stability and scale up to cGMP standards, and perform pre-clinical and clinical studies.
Mr. Kenneth Kirby
Clients in focus...